Product
Whole-human anti-tetanus toxin monoclonal antibody A82 / B86
1 clinical trial
1 indication
Indication
Clostridium tetaniClinical trial
Multicenter, Randomized, Blinded, Controlled Phase I / Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection CombinationStatus: Not yet recruiting, Estimated PCD: 2024-10-30